BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21353103)

  • 1. Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials.
    Ziakas PD; Kourbeti IS; Voulgarelis M; Mylonakis E
    Clin Ther; 2010 Dec; 32(14):2316-36. PubMed ID: 21353103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
    Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empiric antifungal therapy in patients with febrile neutropenia.
    Ferrara JJ; MacDougall C; Gallagher JC
    Pharmacotherapy; 2011 Apr; 31(4):369-85. PubMed ID: 21449626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.
    Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Suguro M; Arai C; Matsuyama T; Takezako N; Miwa A; Kern W; Kami M; Akiyama H; Hirai H; Togawa A
    Cancer; 2000 Oct; 89(7):1611-25. PubMed ID: 11013378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
    Glasmacher A; Prentice A; Gorschlüter M; Engelhart S; Hahn C; Djulbegovic B; Schmidt-Wolf IG
    J Clin Oncol; 2003 Dec; 21(24):4615-26. PubMed ID: 14673051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis.
    Karthaus M; Hentrich M
    Mycoses; 2011 Jan; 54 Suppl 1():1-6. PubMed ID: 21126265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
    Vardakas KZ; Michalopoulos A; Falagas ME
    Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
    J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults.
    Rex JH; Anaissie EJ; Boutati E; Estey E; Kantarjian H
    Leukemia; 2002 Jun; 16(6):1197-9. PubMed ID: 12040453
    [No Abstract]   [Full Text] [Related]  

  • 11. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.
    Kibbler CC
    Mycoses; 1999; 42 Suppl 2():121-4. PubMed ID: 10865918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
    Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
    Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fungal infections: current diagnosis and treatment.
    Cordonnier C
    Hematol J; 2004; 5 Suppl 3():S59-62. PubMed ID: 15190280
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients.
    Moeremans K; Annemans L
    Expert Opin Pharmacother; 2006 Oct; 7(14):1931-43. PubMed ID: 17020419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of fungal infections in the immunocompromised host.
    Mahfouz T; Anaissie E
    Curr Opin Investig Drugs; 2003 Aug; 4(8):974-90. PubMed ID: 14508882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prophylaxis of fungal infections in haematological patients: contra].
    Schwartz S
    Dtsch Med Wochenschr; 2010 Sep; 135(38):1871. PubMed ID: 20842608
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prevention of fungal infections in children and adolescents with cancer].
    Groll AH; Ritter J; Müller FM
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A50-68. PubMed ID: 11577364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment on: Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Cornely OA; Ullmann AJ; Karthaus M
    J Antimicrob Chemother; 2006 Jan; 57(1):151-2; author reply 152-4. PubMed ID: 16314347
    [No Abstract]   [Full Text] [Related]  

  • 20. Mortality rates in comparative trials of formulations of amphotericin B.
    Frothingham R
    Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.